T
Toni K. Choueiri
Researcher at Harvard University
Publications - 1230
Citations - 84800
Toni K. Choueiri is an academic researcher from Harvard University. The author has contributed to research in topics: Renal cell carcinoma & Sunitinib. The author has an hindex of 107, co-authored 1071 publications receiving 59514 citations. Previous affiliations of Toni K. Choueiri include University of Ulsan & University of British Columbia.
Papers
More filters
Journal ArticleDOI
The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma
TL;DR: The current clinical data with VEGF-targeted approaches in RCC is described and plans for future development are described, including monotherapy or in combination with many trials still in progress.
Journal ArticleDOI
Geographic Distribution of Racial Differences in Prostate Cancer Mortality.
Sean A. Fletcher,Sean A. Fletcher,Maya Marchese,Alexander P. Cole,Brandon A. Mahal,David F. Friedlander,Marieke J. Krimphove,Kerry L. Kilbridge,Stuart R. Lipsitz,Paul L. Nguyen,Toni K. Choueiri,Adam S. Kibel,Quoc-Dien Trinh +12 more
TL;DR: It is suggested that race-based survival differences in prostate cancer vary regionally, which may allow for targeted interventions to mitigate these disparities.
Journal ArticleDOI
Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT).
Robert J. Motzer,Naomi B. Haas,Frede Donskov,Marine Gross-Goupil,Sergei Varlamov,Evgeny Kopyltsov,Jae-Lyun Lee,Bohuslav Melichar,Brian I. Rini,Toni K. Choueiri,Milada Zemanova,Lori Wood,Dirk Fahlenkamp,M.N. Reaume,Arnulf Stenzl,Weichao Bao,Paola Aimone,Christian Doehn,Paul Russo,Cora N. Sternberg +19 more
TL;DR: The safety and efficacy of pazopanib (PAZ) versus placebo in patients with locally advanced renal cell carcinoma (RCC) post nephrectomy is evaluated with NCT01235962.
Journal ArticleDOI
Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma.
Thomas Seisen,Tarun Jindal,Patrick Karabon,Akshay Sood,Joaquim Bellmunt,Morgan Rouprêt,Jeffrey J. Leow,Malte W. Vetterlein,Maxine Sun,Shaheen Alanee,Toni K. Choueiri,Quoc-Dien Trinh,Mani Menon,Firas Abdollah +13 more
TL;DR: Findings show a net OS benefit for fit patients who received chemotherapy plus RNU for mUTUC relative to their counterparts treated with chemotherapy alone, and such treatment may be associated with an overall survival benefit compared to chemotherapy alone in fit patients.
Journal ArticleDOI
Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials.
Pooja Ghatalia,Youjin Je,Nemer R. El Mouallem,Paul L. Nguyen,Quoc-Dien Trinh,Guru Sonpavde,Toni K. Choueiri +6 more
TL;DR: A meta-analysis of randomized controlled trials (RCT) was conducted to determine the relative risk of hepatotoxicity with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and the incidence of hepatic failure with VEGFR TKIs was 0.8%.